Literature DB >> 6435066

Titration streptomycin therapy for bilateral Meniere's disease: a preliminary report.

M D Graham, R T Sataloff, J L Kemink.   

Abstract

Intramuscular dosages of streptomycin sulfate were titrated in eight patients with bilateral Meniere's disease in an attempt to alleviate disabling vertigo and hearing loss. It appears possible to eliminate the vertiginous episodes, preserve or improve hearing, and avoid ataxia and oscillopsia in most of these individuals. At present we consider this treatment regimen our first choice of therapy in people with bilateral active Meniere's disease or in patients whose only hearing ear is actively fluctuating and in whom associated disabling vertigo is present. Great caution and supervision should be exercised in the use of streptomycin titration therapy in the individual with bilateral Meniere's disease, as further experience is required to determine the efficacy of this form of management.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6435066     DOI: 10.1177/019459988409200413

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  5 in total

Review 1.  Ménière's disease.

Authors:  S N Merchant; S D Rauch; J B Nadol
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

Review 2.  Menière's disease: pathophysiology and treatment.

Authors:  H Thai-Van; M J Bounaix; B Fraysse
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Neurological manifestations and toxicities of the antituberculosis drugs. A review.

Authors:  M R Holdiness
Journal:  Med Toxicol       Date:  1987 Jan-Feb

Review 4.  Advances in nano-based inner ear delivery systems for the treatment of sensorineural hearing loss.

Authors:  Lilun Li; Tiffany Chao; Jason Brant; Bert O'Malley; Andrew Tsourkas; Daqing Li
Journal:  Adv Drug Deliv Rev       Date:  2016-01-12       Impact factor: 15.470

Review 5.  Nanocarriers for Inner Ear Disease Therapy.

Authors:  Xiaoxiang Xu; Jianwei Zheng; Yanze He; Kun Lin; Shuang Li; Ya Zhang; Peng Song; Yuye Zhou; Xiong Chen
Journal:  Front Cell Neurosci       Date:  2021-12-03       Impact factor: 5.505

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.